2-DPMP
Discover related
2 sources
How the databases line up — = agree, ≈ partial, ≠ differ. In lists, shared items appear in every source and unique ones in only one (matched case-insensitively).
Show:
| TripSit | Pharmacology | ||
|---|---|---|---|
| Classification | |||
| Class / category | — | ||
| Also known as | desoxypipradrol2dpmp2-desoxypiperadoldesoxypipradol | — | |
| Safety | |||
| Dose · Insufflated | |||
| Threshold | 1 mg | — | |
| Light | 2–3 mg | — | |
| Common | 3–4 mg | — | |
| Strong | 4–6 mg | — | |
| Dose · Oral | |||
| Threshold | 1 mg | — | |
| Light | 2–4 mg | — | |
| Common | 4–6 mg | — | |
| Strong | 6–8 mg | — | |
| Duration | |||
| Onset | 60–120 minutes | — | |
| Total | 16–72 hours | — | |
| After-effects | 1–72 hours | — | |
| Pharmacology | |||
| Receptor activity | — | Cytochrome P450 1B1Cytochrome P450 1A1 | |
TripSit summary
A very potent stimulant that is a NDRI. Developed by Novartis in the 1950s, to treat narcolepsy and ADHD, however dropped when Methylphenidate was produced a few years later, which was seen as superior due to its shorter T½. 2-DPMP Half life 16-20 hours. Warning: subjective reports suggest this drug is caustic to the nasal mucosa and may cause damage to the nasal cavity.
Fact-sheets from PsychonautWiki. Harm-reduction reference only — not medical advice.